These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 17180805)

  • 1. [Clinical investigation on administration method of gatifloxacin based on PK/PD theory].
    Mikamo H; Tanaka K; Watanabe K; Tamaya T; Izumi K
    Jpn J Antibiot; 2006 Oct; 59(5):364-72. PubMed ID: 17180805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The proper use of quinolones to the elderly patient with community-acquired pneumonia examined by Monte Carlo simulation].
    Yanagihara K; Morinaga Y; Fukushima K; Nakamura S; Kurihara S; Seki M; Izumikawa K; Kakeya H; Yamamoto Y; Miyazaki Y; Hirakata Y; Tashiro T; Kohno S
    Jpn J Antibiot; 2007 Oct; 60(5):251-6. PubMed ID: 18198653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model.
    Ambrose PG; Forrest A; Craig WA; Rubino CM; Bhavnani SM; Drusano GL; Heine HS
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4351-5. PubMed ID: 17875992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prediction on the efficacy of fluoroquinolones for anaerobic infections using Monte Carlo simulation].
    Mikamo H; Tanaka K; Watanabe K
    Jpn J Antibiot; 2007 Dec; 60(6):335-43. PubMed ID: 18447205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical investigation on target value of T>MIC in carbapenems].
    Mikamo H; Yamagishi Y; Tanaka K; Watanabe K
    Jpn J Antibiot; 2008 Apr; 61(2):73-81. PubMed ID: 18669417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.
    Zinner SH; Vostrov SN; Alferova IV; Lubenko IY; Portnoy YA; Firsov AA
    Int J Antimicrob Agents; 2004 Aug; 24(2):173-7. PubMed ID: 15288317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [In vitro short-term bactericidal activity and accumulation of NM394, the active metabolite of prulifloxacin, for Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa: comparison with ciprofloxacin, levofloxacin, and gatifloxacin].
    Shimizu M; Tabata M; Hara T; Araake M; Watabe H; Nishino T
    Jpn J Antibiot; 2002 Dec; 55(6):791-9. PubMed ID: 12621733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of clinical dosage of gatifloxacin for respiratory tract infections in elderly patients based on pharmacokinetics/pharmacodynamics (PK/PD).
    Niki Y; Yoshida K; Miyashita N; Oka M; Hara H; Kishimoto M; Okimoto N; Kawanishi M; Uno M; Kamao T; Yoneyama H; Nakamura J; Kimura M; Watanabe M; Tanimukai T; Moriya O; Matsushima T
    J Infect Chemother; 2008 Aug; 14(4):296-304. PubMed ID: 18709533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antibacterial activity of gatifloxacin against various fresh clinical isolates in 2002].
    Matsuzaki K; Watabe E; Yoshimori K; Shikano M; Sato Y; Hasegawa M; Kobayashi I
    Jpn J Antibiot; 2002 Dec; 55(6):800-7. PubMed ID: 12621734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The pharmacodynamics and pharmacokinetics of fluoroquinolones in the evaluation of antibacterial therapy regimens].
    Smirnova LB; Sokolova VI
    Antibiot Khimioter; 2000; 45(7):14-6. PubMed ID: 10987102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits.
    Proksch JW; Ward KW
    J Ocul Pharmacol Ther; 2010 Oct; 26(5):449-58. PubMed ID: 20874668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Perioperative antibiotics effectiveness on conjunctival flora and microbial sensitivity].
    Arakaki Y; Hayakawa K; Mori F; Kojima M; Masahara H; Matsushita T; Mori Y; Eguchi S
    Nippon Ganka Gakkai Zasshi; 2009 Sep; 113(9):906-12. PubMed ID: 19882928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones.
    Segreti J; Jones RN; Bertino JS
    J Ocul Pharmacol Ther; 2012 Feb; 28(1):3-11. PubMed ID: 21999341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gatifloxacin: a review of its use in the management of bacterial infections.
    Perry CM; Ormrod D; Hurst M; Onrust SV
    Drugs; 2002; 62(1):169-207. PubMed ID: 11790160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of gatifloxacin in children with recurrent otitis media: application of sparse sampling in clinical development.
    Rubino CM; Ambrose P; Cirincione B; Arguedas A; Sher L; Lopez E; Sáez-Llorens X; Grasela DM
    Diagn Microbiol Infect Dis; 2007 Sep; 59(1):67-74. PubMed ID: 17875453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integration of pharmacokinetic and pharmacodynamic indices of marbofloxacin in turkeys.
    Haritova AM; Rusenova NV; Parvanov PR; Lashev LD; Fink-Gremmels J
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3779-85. PubMed ID: 16940071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interference of sub-inhibitory concentrations of gatifloxacin on various determinants of bacterial virulence.
    Dal Sasso M; Bovio C; Culici M; Braga PC
    J Chemother; 2002 Oct; 14(5):473-82. PubMed ID: 12462427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative minimal inhibitory and mutant prevention drug concentrations of four fluoroquinolones against ocular isolates of Haemophilus influenzae.
    Hedlin P; Blondeau JM
    Eye Contact Lens; 2007 May; 33(3):161-4. PubMed ID: 17502752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of gatifloxacin pharmacokinetics and pharmacodynamics in severely ill adults in a medical Intensive Care Unit.
    Fish DN
    Int J Antimicrob Agents; 2007 Jun; 29(6):715-23. PubMed ID: 17433631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antibacterial activity of oral cephems against various clinically isolated strains and evaluation of efficacy based on the pharmacokinetics/pharmacodynamics theory].
    Nakamura T; Takahashi H
    Jpn J Antibiot; 2004 Dec; 57(6):465-74. PubMed ID: 15747584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.